FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146673033> ?p ?o ?g. }

• W2146673033 endingPage "894" @default.
• W2146673033 startingPage "884" @default.
• W2146673033 abstract "AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered in different dosing schedules.AZD5438 was administered four times daily, once every 7 days (study 1), for 14 consecutive days followed by 7 days of rest (study 2), or continuously (study 3), to patients with advanced solid tumours. Dose escalation proceeded until the emergence of dose-limiting toxic effects.Sixty-four patients were included across the three studies (19, 17 and 28, respectively). Nausea and vomiting were the most common adverse events. When dosed continuously, 40 mg four times daily was considered intolerable, and due to safety issues, all studies were terminated prematurely. Consequently, no intolerable dose was identified during the weekly schedule. Pharmacokinetics demonstrated dose-proportional exposure, high interpatient variability and accumulation after multiple doses. Skin biopsies indicated reduced retinoblastoma protein phosphorylation at cdk2 phospho-sites; other pharmacodynamic assessments did not reveal consistent trends.AZD5438 was generally well tolerated in a weekly dosing schedule, but not in continuous schedules. The clinical development programme for AZD5438 was discontinued owing to tolerability and exposure data from these studies." @default.
• W2146673033 created "2016-06-24" @default.
• W2146673033 creator A5000418012 @default.
• W2146673033 creator A5005285729 @default.
• W2146673033 creator A5006913373 @default.
• W2146673033 creator A5024294734 @default.
• W2146673033 creator A5045419282 @default.
• W2146673033 creator A5047677453 @default.
• W2146673033 creator A5048419838 @default.
• W2146673033 creator A5051430596 @default.
• W2146673033 creator A5055792960 @default.
• W2146673033 creator A5060648247 @default.
• W2146673033 creator A5070212769 @default.
• W2146673033 creator A5081130122 @default.
• W2146673033 creator A5086112432 @default.
• W2146673033 creator A5086473468 @default.
• W2146673033 creator A5089159833 @default.
• W2146673033 date "2010-04-01" @default.
• W2146673033 modified "2023-10-16" @default.
• W2146673033 title "Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours" @default.
• W2146673033 cites W1973586213 @default.
• W2146673033 cites W1985826737 @default.
• W2146673033 cites W1988050012 @default.
• W2146673033 cites W1991054314 @default.
• W2146673033 cites W1991447150 @default.
• W2146673033 cites W2021457628 @default.
• W2146673033 cites W2022387751 @default.
• W2146673033 cites W2029080338 @default.
• W2146673033 cites W2032009624 @default.
• W2146673033 cites W2040611519 @default.
• W2146673033 cites W2098203835 @default.
• W2146673033 cites W2105934245 @default.
• W2146673033 cites W2119874496 @default.
• W2146673033 cites W2128102073 @default.
• W2146673033 cites W2137086876 @default.
• W2146673033 cites W2139176340 @default.
• W2146673033 cites W2139248078 @default.
• W2146673033 cites W2150508157 @default.
• W2146673033 cites W2171852242 @default.
• W2146673033 cites W2177166422 @default.
• W2146673033 cites W31572314 @default.
• W2146673033 doi "https://doi.org/10.1093/annonc/mdp377" @default.
• W2146673033 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2844945" @default.
• W2146673033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19825886" @default.
• W2146673033 hasPublicationYear "2010" @default.
• W2146673033 type Work @default.
• W2146673033 sameAs 2146673033 @default.
• W2146673033 citedByCount "48" @default.
• W2146673033 countsByYear W21466730332012 @default.
• W2146673033 countsByYear W21466730332013 @default.
• W2146673033 countsByYear W21466730332014 @default.
• W2146673033 countsByYear W21466730332015 @default.
• W2146673033 countsByYear W21466730332016 @default.
• W2146673033 countsByYear W21466730332017 @default.
• W2146673033 countsByYear W21466730332018 @default.
• W2146673033 countsByYear W21466730332019 @default.
• W2146673033 countsByYear W21466730332020 @default.
• W2146673033 countsByYear W21466730332021 @default.
• W2146673033 countsByYear W21466730332022 @default.
• W2146673033 countsByYear W21466730332023 @default.
• W2146673033 crossrefType "journal-article" @default.
• W2146673033 hasAuthorship W2146673033A5000418012 @default.
• W2146673033 hasAuthorship W2146673033A5005285729 @default.
• W2146673033 hasAuthorship W2146673033A5006913373 @default.
• W2146673033 hasAuthorship W2146673033A5024294734 @default.
• W2146673033 hasAuthorship W2146673033A5045419282 @default.
• W2146673033 hasAuthorship W2146673033A5047677453 @default.
• W2146673033 hasAuthorship W2146673033A5048419838 @default.
• W2146673033 hasAuthorship W2146673033A5051430596 @default.
• W2146673033 hasAuthorship W2146673033A5055792960 @default.
• W2146673033 hasAuthorship W2146673033A5060648247 @default.
• W2146673033 hasAuthorship W2146673033A5070212769 @default.
• W2146673033 hasAuthorship W2146673033A5081130122 @default.
• W2146673033 hasAuthorship W2146673033A5086112432 @default.
• W2146673033 hasAuthorship W2146673033A5086473468 @default.
• W2146673033 hasAuthorship W2146673033A5089159833 @default.
• W2146673033 hasBestOaLocation W21466730331 @default.
• W2146673033 hasConcept C111113717 @default.
• W2146673033 hasConcept C112705442 @default.
• W2146673033 hasConcept C197934379 @default.
• W2146673033 hasConcept C2777288759 @default.
• W2146673033 hasConcept C2778375690 @default.
• W2146673033 hasConcept C2780580376 @default.
• W2146673033 hasConcept C2780852908 @default.
• W2146673033 hasConcept C42219234 @default.
• W2146673033 hasConcept C71924100 @default.
• W2146673033 hasConcept C98274493 @default.
• W2146673033 hasConceptScore W2146673033C111113717 @default.
• W2146673033 hasConceptScore W2146673033C112705442 @default.
• W2146673033 hasConceptScore W2146673033C197934379 @default.
• W2146673033 hasConceptScore W2146673033C2777288759 @default.
• W2146673033 hasConceptScore W2146673033C2778375690 @default.
• W2146673033 hasConceptScore W2146673033C2780580376 @default.
• W2146673033 hasConceptScore W2146673033C2780852908 @default.
• W2146673033 hasConceptScore W2146673033C42219234 @default.
• W2146673033 hasConceptScore W2146673033C71924100 @default.
• W2146673033 hasConceptScore W2146673033C98274493 @default.
• W2146673033 hasFunder F4320310274 @default.

• next